Department for ENT Diseases, Sechenov University, Moscow, Russia.
Institute for Regenerative Medicine, Sechenov University, Moscow, Russia.
Stem Cell Res Ther. 2023 Oct 21;14(1):303. doi: 10.1186/s13287-023-03534-x.
There is growing interest to application of regenerative medicine approaches in otorhinolaryngological practice, especially in the framework of the therapy of vocal fold (VF) scar lesions. The used conservative and surgical methods, despite the achieved positive outcomes, are frequently unpredictable and do not result in the restoration of the VF's lamina propria's structure, which provides the mechanical properties necessary for vibration. In this connection, the aim of this study was to ascertain the safety and efficacy of a bioequivalent in the treatment of VF scars using a rabbit model of chronic damage.
The bioequivalent consisted of a hydrogel system based on a PEG-fibrin conjugate and human bone marrow-derived MSC. It was characterized and implanted heterotopically into rats and orthotopically into rabbits after VF scar excision.
We showed that the fabricated bioequivalent consisted of viable cells retaining their metabolic and proliferative activity. While being implanted heterotopically, it had induced the low inflammatory reaction in 7 days and was well tolerated. The orthotopic implantation showed that the gel application was characterized by a lower hemorrhage intensity (p = 0.03945). The intensity of stridor and respiratory rate between the groups in total and between separate groups had no statistically significant difference (p = 0.96 and p = 1; p = 0.9593 and p = 0.97…1, respectively). In 3 days post-implantation, MSC were detected only in the tissues closely surrounding the VF defect. The bioequivalent injection caused that the scar collagen fibers were packed looser and more frequently mutually parallel that is inherent in the native tissue (p = 0.018). In all experimental groups, the fibrous tissue's ingrowth in the adjacent exterior muscle tissue was observed; however, in Group 4 (PEG-Fibrin + MSC), it was much less pronounced than it was in Group 1 (normal saline) (p = 0.008). The difference between the thicknesses of the lamina propria in the control group and in Group 4 was not revealed to be statistically significant (p = 0.995). The Young's modulus of the VF after the bioequivalent implantation (1.15 ± 0.25 kPa) did not statistically significantly differ from the intact VF modulus (1.17 ± 0.45 kPa); therefore, the tissue properties in this group more closely resembled the intact VF.
The developed bioequivalent showed to be biocompatible and highly efficient in the restoration of VF's tissue.
再生医学方法在耳鼻喉科实践中的应用越来越受到关注,特别是在治疗声带(VF)瘢痕病变方面。尽管保守和手术方法取得了积极的效果,但这些方法往往不可预测,并且不能恢复 VF 固有层的结构,而固有层的结构为振动提供了必要的机械性能。因此,本研究的目的是通过慢性损伤的兔模型,确定使用生物等效物治疗 VF 瘢痕的安全性和有效性。
生物等效物由基于 PEG-纤维蛋白缀合物和人骨髓来源 MSC 的水凝胶系统组成。它在 VF 瘢痕切除后在大鼠中异位植入,并在兔中原位植入。
我们表明,所制备的生物等效物由具有代谢和增殖活性的活细胞组成。在异位植入时,它在 7 天内引起低度炎症反应,并且耐受性良好。原位植入显示凝胶应用的出血强度较低(p=0.03945)。各组总呼吸困难和呼吸频率以及各组之间的呼吸困难和呼吸频率均无统计学差异(p=0.96 和 p=1;p=0.9593 和 p=0.97…1,分别)。植入后 3 天,仅在 VF 缺陷周围的组织中检测到 MSC。生物等效物注射导致瘢痕胶原纤维排列更疏松,更频繁地相互平行,这是固有组织的特征(p=0.018)。在所有实验组中,均观察到纤维组织向内生长到相邻的外肌组织中;然而,在第 4 组(PEG-纤维蛋白+MSC)中,与第 1 组(生理盐水)相比,这种情况要明显得多(p=0.008)。对照组和第 4 组固有层厚度之间的差异无统计学意义(p=0.995)。生物等效物植入后 VF 的杨氏模量(1.15±0.25 kPa)与完整 VF 模量(1.17±0.45 kPa)无统计学差异;因此,该组的组织特性更接近完整 VF。
所开发的生物等效物表现出良好的生物相容性和高效恢复 VF 组织的能力。